Tissue Regenix Group PLC
LSE:TRX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0725
59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Tissue Regenix Group PLC
LSE:TRX
|
5.2m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.8B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -195 650% |
| 30th Percentile | 0% |
| Median | 0.1% |
| 70th Percentile | 0.2% |
| Max | 4 630.7% |
Other Profitability Ratios
Tissue Regenix Group PLC
Glance View
Tissue Regenix Group Plc is a medical technology company, which develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine. The company is headquartered in Leeds, West Yorkshire and currently employs 79 full-time employees. The company went IPO on 2006-12-21. The firm is focused on the development of regenerative products using its two platform technologies: decellularization (dCELL), which is used to produce allograft (DermaPure) and xenograft (OrthoPure XT) soft tissue products to promote healing and regeneration, and BioRinse, which is a natural bone filler solution verified to be osteoinductive to stimulate and regenerate native bone growth. The firm is engaged in transforming the treatment of patients in surgical applications, including BioSurgery, Orthopaedics (sports medicine/spine), Dental, General, Plastic Surgery, Urology/Gynaecology, Ophthalmology and Cardiac.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Tissue Regenix Group PLC is 0%, which is in line with its 3-year median of 0%.
Over the last 3 years, Tissue Regenix Group PLC’s Operating Margin has increased from -20.8% to 0%. During this period, it reached a low of -20.8% on May 30, 2022 and a high of 1.5% on Dec 31, 2024.